Perspective

The Dawn of the SPPARMs?

Science's STKE  26 Feb 2002:
Vol. 2002, Issue 121, pp. pe9
DOI: 10.1126/stke.2002.121.pe9

You are currently viewing the abstract.

View Full Text

Abstract

Thiazolidinediones (TZDs) are used as antidiabetic agents in the treatment of type II diabetes. These compounds are ligands for the nuclear hormone receptor PPARγ, which is highly expressed in adipose tissue. PPARγ acts as a molecular switch in the process of fat cell development. The quest for the ideal antidiabetic agent is challenged by the need to develop PPARγ ligands that improve insulin sensitivity, but do not promote fat cell formation. A newly described PPARγ ligand may represent an initial step in this direction and could lead to improved agents for treating insulin resistance in type II diabetes.

View Full Text